Author/Authors :
Alyamkina، نويسنده , , Ekaterina A. and Leplina، نويسنده , , Olga Y. and Ostanin، نويسنده , , Alexandr A. and Chernykh، نويسنده , , Elena R. and Nikolin، نويسنده , , Valeriy P. and Popova، نويسنده , , Nelly A. and Proskurina، نويسنده , , Anastasia S. and Gvozdeva، نويسنده , , Tatiana S. and Dolgova، نويسنده , , Evgenia V. and Orishchenko، نويسنده , , Konstantin E. and Rogachev، نويسنده , , Vladimir A. and Sidorov، نويسنده , , Sergey V. and Varaksin، نويسنده , , Nikolay A. and Ryabicheva، نويسنده , , Tatiana G. and Bogachev، نويسنده , , Sergey S. and Shurdov، نويسنده , , Mikhail A.، نويسنده ,
Abstract :
We investigated the influence of Panagen DNA preparations on laboratory animals and IFN-induced human dendritic cells, as well as analyzed the data from a phase II clinical trial in the therapy of breast cancer. It was shown that this treatment resulted in increased number of CD8+/perforin+ T cells in peripheral lymphoid organs of experimental animals, in mixed lymphocyte culture population and in peripheral blood of breast cancer patients. Moreover, we demonstrated that when Panagen DNA preparations are used in combination with the standard FAC-based breast cancer therapies, non-specific immune response activity remains at the same levels as observed prior to therapy, whereas in FAC-placebo patients, non-specific immunity is greatly diminished.
Keywords :
CD8+/perforin+ T cells , Mixed lymphocyte culture , Human fragmented double-stranded DNA , adaptive immunity
